Table 1. Demographics by Treatment Group (Intent-to-Treat Population).
| Children (2–17 y) | Adults (18–49 y) | |||
| Baseline Characteristics | H1N1 LAIV | Placebo | H1N1 LAIV | Placebo |
| n | 261 | 65 | 240 | 60 |
| Age, y | ||||
| Mean (SD) | 8.9 (4.3) | 9.2 (4.3) | 33.3 (9.2) | 34.1 (8.9) |
| Median | 8.0 | 10.0 | 33.0 | 32.0 |
| Minimum–maximum | 2–17 | 2–17 | 18–49 | 18–49 |
| Age group, n (%) | ||||
| 2–8 y | 133 (51.0) | 31 (47.7) | NA | NA |
| 9–17 y | 128 (49.0) | 34 (52.3) | NA | NA |
| Gender, n (%) | ||||
| Male | 131 (50.2) | 29 (44.6) | 102 (42.5) | 27 (45.0) |
| Female | 130 (49.8) | 36 (55.4) | 138 (57.5) | 33 (55.0) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 50 (19.2) | 17 (26.2) | 95 (39.6) | 18 (30.0) |
| Non–Hispanic or –Latino | 211 (80.8) | 48 (73.8) | 145 (60.4) | 42 (70.0) |
| Race, n (%) | ||||
| American Indian or Alaskan Native | 4 (1.5) | 0 (0.0) | 1 (0.4) | 0 (0.0) |
| Asian | 2 (0.8) | 4 (6.2) | 0 (0.0) | 0 (0.0) |
| Black or African American | 43 (16.5) | 12 (18.5) | 37 (15.4) | 13 (21.7) |
| Native Hawaiian or Pacific Islander | 2 (0.8) | 0 (0.0) | 1 (0.4) | 0 (0.0) |
| White | 198 (75.9) | 43 (66.2) | 199 (82.9) | 47 (78.3) |
| Other | 4 (1.5) | 5 (7.7) | 1 (0.4) | 0 (0.0) |
| Multiracial | 8 (3.1) | 1 (1.5) | 1 (0.4) | 0 (0.0) |
LAIV = live attenuated influenza vaccine; NA = not applicable.